knowledge -WSS

knowledge

author：explore 2025-09-27 13:04:13 - browse：9

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cord blood banking comes at a high cost to babies

leisure time

WSS

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

After affirmative action ruling, medical educators look to 'holistic review'

Medicare proposal to cover medical devices draws a mixed reaction

Duchenne breakthrough therapy leaves behind pioneering families

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Guidelines to prevent youth baseball injuries need more muscle

ASCO: Palliative care found as helpful given virtually as in person

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wildfire smoke exposes gaps in outdoor worker protections

Guidelines to prevent youth baseball injuries need more muscle

After affirmative action ruling, medical educators look to 'holistic review'

Bright Health sells Medicare Advantage business to Molina

In age of alternative facts, a scholarly course on calling out crap

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

knowledge

Heart attack and stroke risk calculators need revising

Change Healthcare can notify patients about the breach, HHS says

See how much Covid

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

At ASCO, AstraZeneca reports strong data for breast cancer drug

Medical leaders decry Supreme Court decision on affirmative action

leisure time

focus

knowledge

knowledge